Parabilis Medicines, Inc.

We are a clinical-stage biopharmaceutical company built to develop transformative medicines addressing some of the most consequential, yet historically undruggable, protein targets driving human disease. We leverage our proprietary platform to pioneer a novel therapeutic modality, Helicons, which are stabilized helical peptides engineered to bind and precisely modulate proteins that have long been beyond the reach of conventional medicines.

Current securities

1. Regulation FD DisclosureSep 15, 2026
2. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory ArrangementsSep 2, 2026
3. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements · Regulation FD DisclosureAug 25, 2026
4. SCHEDULE 13G filingAug 14, 2026
5. Results of Operations and Financial Condition · Regulation FD DisclosureAug 13, 2026